Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the spanish BIOBADASER registry

Moreno-Ramos, Manuel José; Sánchez-Piedra, Carlos; Martínez-González, Olga; Rodríguez-Lozano, Carlos; Pérez-García, Carolina; Freire, Mercedes; Campos, Cristina; Cáliz-Caliz, Rafael; Calvo, Jerusalem; Blanco-Madrigal, Juan M.; Pérez-Gómez, Ana; Moreno-Martínez, María José; Linares, Luis; Sánchez-Alonso, Fernando; Sastré, Carlos; Castrejón, Isabel

Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the spanish BIOBADASER registry

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Moreno-Ramos, Manuel José
dc.contributor.author Sánchez-Piedra, Carlos
dc.contributor.author Martínez-González, Olga
dc.contributor.author Rodríguez-Lozano, Carlos
dc.contributor.author Pérez-García, Carolina
dc.contributor.author Freire, Mercedes
dc.contributor.author Campos, Cristina
dc.contributor.author Cáliz-Caliz, Rafael
dc.contributor.author Calvo, Jerusalem
dc.contributor.author Blanco-Madrigal, Juan M.
dc.contributor.author Pérez-Gómez, Ana
dc.contributor.author Moreno-Martínez, María José
dc.contributor.author Linares, Luis
dc.contributor.author Sánchez-Alonso, Fernando
dc.contributor.author Sastré, Carlos
dc.contributor.author Castrejón, Isabel
dc.date.accessioned 2022-12-05T08:03:43Z
dc.date.available 2022-12-05T08:03:43Z
dc.date.issued 2022
dc.description.abstract Rheumatic diseases are extensively managed with biological disease-modifying antirheumatic drugs (bDMARDs), but a notable proportion of patients withdraw in the long term because of lack of effectiveness, adverse events, or the patient's decision. The present real-world analysis showed the effectiveness, retention, and safety data collected in the Spanish BIOBADASER registry for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA, including ankylosing spondylitis (AS) and non-radiographic axSpA) treated with secukinumab, a human antibody against interleukin-17A (IL-17A), for more than 12 months. Six hundred and thirty-nine patients were analysed (350, 262, and 27 PsA, AS, and nr-axSpA patients, respectively). The results showed an improvement in the disease activity after 1 year of treatment, in terms of decreases of the mean Disease Activity Score 28 using C-reactive protein (DAS28-CRP), the mean Disease Activity Psoriatic Arthritis (DAPSA) score, swollen joint counts (SJC), and tender joint counts (TJC) in PsA patients and decreases in the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the mean Ankylosing Spondylitis Disease Activity Score (ASDAS) in axSpA patients. This improvement was maintained or increased after 2 and 3 years of treatment, indicating that secukinumab is effective in both naïve and non-responder patients. Retention rates were higher when secukinumab was used as the first-line biological treatment, although they were also adequate in the second and third lines of treatment. Collected safety data were consistent with previous reports.
dc.format.mimetype application/pdf
dc.identifier.citation Moreno-Ramos MJ, Sanchez-Piedra C, Martínez-González O, Rodríguez-Lozano C, Pérez-Garcia C, Freire M, et al. Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the spanish BIOBADASER registry. Rheumatol Ther. 2022 Aug; 9(4): 1031- 47. DOI: 10.1007/s40744-022-00446
dc.identifier.doi http://dx.doi.org/10.1007/s40744-022-00446
dc.identifier.issn 2198-6576
dc.identifier.uri http://hdl.handle.net/10230/55082
dc.language.iso eng
dc.publisher SpringerOpen
dc.rights Copyright © Moreno-Ramos MJ, Sanchez-Piedra C, Martínez-González O, Rodríguez-Lozano C, Pérez-Garcia C, Freire M, et al. 2022, corrected publication 2022. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
dc.subject.keyword Ankylosing spondylitis
dc.subject.keyword Axial spondyloarthritis
dc.subject.keyword IL-17
dc.subject.keyword Non-radiographic axial spondyloarthrtis
dc.subject.keyword Psoriatic arthritis
dc.subject.keyword Secukinumab
dc.title Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the spanish BIOBADASER registry
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)